Pro Investor research
Sign in to continue.
Full company research for this company is part of the Pro Investor membership: Pro Investor Scores and rankings, the full screener, valuation and capital returns intelligence, ownership and insider evidence, signals and alerts. Company identity, coverage depth and the education library stay free.
ALZN · NASDAQ
ALZAMEND NEURO INC
Private betaSector unavailable · Industry unavailable
$1.72
+1.18%
Close on Sep 11, 2026
Updated 12/18/2023
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Research Collections
This company does not currently satisfy any collection rule. That is a stored research result, not a judgement about the business.
Browse collectionsLearn the metrics on this page
Plain-English definitions, with the formula and the limitations of each measure.
In the company’s own words
What this company does
the context requires otherwise, references to the "Company," "Alzamend," "we," "our company"
and "us" refer to Alzamend Neuro, Inc., a Delaware corporation and its subsidiary.
company focused on developing novel products for the treatment of Alzheimer’s disease ("Alzheimer’s"), bipolar
disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"). With
Quoted from the business section of this company’s 10-K filed July 22, 2026. Read the filing
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.